October 2022 Issue | Blood Cancers Today

October 2022

This issue of Blood Cancers Today features a review of third-line therapy options for CML, meeting news from the 2022 ESMO Congress and 19th Annual IMS Meeting, and more.

Associate Editor's Message

The Future Is Bright for Multiple Myeloma Treatment Options

Features

News

In the Literature

Teclistamab Produces Deep, Durable Responses in Patients with Triple-Class Exposed Relapsed/Refractory Myeloma

Regulatory Actions

EC Grants Conditional Marketing Authorization for Teclistamab in Myeloma

FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Phase I/II Study

FDA Clears IND for IkT-001Pro for the Treatment of CML

EC Grants Marketing Authorization for Melphalan Flufenamide Plus Dexamethasone in Myeloma

FDA Approves Ibrutinib for Pediatric Chronic GVHD

Meeting News

Combination of Lemzoparlimab Plus Azacitidine Shows Promise in Newly Diagnosed Higher-Risk MDS

CAR-T Therapy Shows ‘Durable Responses’ in Ongoing Phase I Trial in Patients with Myeloma

Patients with Myeloma, Secondary Immunodeficiencies Face Higher Burden of Infection, Lower Survival

Carfilzomib, Lenalidomide, and Dexamethasone Improve PFS Over Lenalidomide in Post-AHSCT Myeloma

Real-World Safety, Efficacy of Idecabtagene Vicleucel Similar to Clinical Trial Results

Lenalidomide, Bortezomib, and Dexamethasone Plus AHSCT Leads to Significant PFS Improvement in Myeloma

State of the Art

What Are the Current Strategies for Managing Relapsed MCL?

News Roundup

Azacitidine Plus Venetoclax Leads to High Response Rates in High-Risk MDS, CML

IDH2 Inhibitor Plus HMA Leads to Durable Responses in IDH2-Mutated MDS

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer